Ray Therapeutics Secures PRIME Designation from the European Medicines Agency for RTx-015 Targeting Retinitis Pigmentosa
Ray Therapeutics (RayTx), a clinical-stage biopharmaceutical company focused on developing innovative therapies for vision restoration, has announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to its lead investigational therapy, RTx-015, for the treatment of retinitis pigmentosa (RP). This recognition marks an important regulatory milestone for the company and underscores the growing global support for novel approaches aimed at addressing severe retinal degenerative diseases.
The PRIME designation is reserved for therapies that demonstrate the potential to address significant unmet medical needs and offer meaningful clinical benefits over existing treatment options. It is typically granted based on early clinical data or compelling nonclinical evidence, and it provides developers with enhanced regulatory guidance and accelerated pathways for development and review. In the case of RTx-015, the designation highlights the therapy’s promise in tackling a condition that currently lacks effective treatment options, particularly in its advanced stages.
This latest regulatory achievement builds on momentum from the United States, where RTx-015 recently received the Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) in April 2026. Together, the EMA’s PRIME and the FDA’s RMAT designations reinforce confidence in the therapy’s scientific foundation and clinical potential, while also facilitating closer collaboration with regulatory agencies to expedite development and potential approval.
Paul Bresge, Chief Executive Officer and Co-Founder of Ray Therapeutics, emphasized the significance of these dual designations. He noted that receiving PRIME designation from the EMA, in addition to RMAT status from the FDA, serves as a strong validation of both the company’s underlying science and the encouraging clinical data generated to date. He also highlighted the urgent unmet need in retinitis pigmentosa, a condition that affects more than one million people globally, many of whom currently have no therapeutic options to preserve or restore vision. According to Bresge, these regulatory recognitions will help accelerate the advancement of RTx-015 and support the company’s broader mission of restoring sight to individuals living with blinding retinal diseases.
RTx-015 represents a novel, first-in-class optogenetic gene therapy designed to restore vision in patients with retinal degeneration, regardless of the specific genetic mutation underlying the disease. Unlike traditional gene therapies that target individual genetic defects, RTx-015 takes a genotype-independent approach, making it potentially applicable to a much broader patient population. The therapy is administered through a single intravitreal injection, a minimally invasive procedure commonly used in ophthalmology, which delivers the therapeutic agent directly into the eye.
The therapy is currently being evaluated for the treatment of retinitis pigmentosa, a group of inherited retinal disorders characterized by the progressive degeneration of photoreceptor cells in the retina. In RP, rod photoreceptors—responsible for vision in low-light conditions—are typically affected first, followed by the degeneration of cone photoreceptors, which are essential for central vision and color perception. As the disease progresses, patients often experience symptoms such as night blindness, loss of peripheral vision (commonly referred to as tunnel vision), and ultimately severe vision impairment or complete blindness.
The burden of retinitis pigmentosa extends beyond vision loss, significantly impacting patients’ independence, mobility, and overall quality of life. Daily activities such as reading, driving, and navigating unfamiliar environments become increasingly difficult as the disease advances. Despite decades of research, treatment options for advanced RP remain extremely limited, highlighting the urgent need for innovative therapeutic strategies like RTx-015.
The EMA’s decision to grant PRIME designation was supported by encouraging preliminary data from an ongoing Phase 1/2 clinical trial involving patients with advanced retinitis pigmentosa. According to the company, early results from the study have demonstrated both a favorable safety profile and signs of efficacy across multiple dose levels. Notably, improvements in visual function were observed in the treated eye among participants, suggesting that RTx-015 may have the potential to restore meaningful vision even in patients with significant photoreceptor loss.
These early findings are particularly significant given the advanced stage of disease in the trial population, where therapeutic intervention has historically been challenging. The observed improvements provide a strong rationale for continued clinical development and further evaluation in larger, controlled studies. If confirmed, these results could represent a major breakthrough in the treatment of inherited retinal diseases.
In addition to offering regulatory advantages, the PRIME designation enables more frequent and proactive engagement with the EMA, including scientific advice and support for optimizing clinical trial design. This collaborative approach is intended to streamline the development process and increase the likelihood of successful outcomes, ultimately bringing promising therapies to patients more quickly.
As Ray Therapeutics continues to advance RTx-015 through clinical development, the combined support from both European and U.S. regulatory authorities positions the program for accelerated progress on a global scale. With millions of individuals affected by retinitis pigmentosa and limited treatment options currently available, the potential impact of a successful therapy could be transformative.
Overall, the granting of PRIME designation to RTx-015 represents a significant step forward in the field of retinal gene therapy. It highlights not only the promise of optogenetic approaches in restoring vision but also the increasing recognition by regulatory agencies of the urgent need to address rare and debilitating conditions like retinitis pigmentosa.
About Ray Therapeutics
Ray Tx is a clinical-stage biopharmaceutical company advancing optogenetic therapies to restore vision in patients with retinal degenerative diseases. By delivering a bioengineered, highly light-sensitive protein to targeted retinal cells, the approach is designed to improve visual function regardless of the underlying genetic mutation.
RTx-015 is Ray Therapeutics’ lead optogenetic gene therapy currently being evaluated in patients with retinitis pigmentosa. Delivered as a single intravitreal injection, the treatment aims to restore functional vision to those with advanced visual impairment.
This research was additionally made possible by funding from the California Institute for Regenerative Medicine (CIRM), a state agency in California that supports research in regenerative medicine, stem cell therapy, gene therapy, and clinical trials (Grant number: CLIN2-17086).
Ray Therapeutics has a second clinical-stage program, RTx-021, which has been designed to restore vision to those with macula diseases, such as Stargardt disease and geographic atrophy age-related macular degeneration (GA AMD) by targeting retinal bipolar cells. Several of these programs are supported by grants from the California Institute for Regenerative Medicine (CIRM).
Source Link:https://www.businesswire.com/
